Innogenetics grants GlaxoSmithKline Biologicals a license for use of HPV SPF10 genotyping technology in clinical studies on HPV
Innogenetics announced that it has granted GlaxoSmithKline Biologicals (GSK) a worldwide non-exclusive restricted license to use its proprietary SPF10 technology in clinical and epidemiological human papillomavirus (HPV) vaccine studies. Innogenetics will receive royalties for each individual test performed during the studies.
Cervical cancer is caused by persistent infection with HPV, and is the second most common cancer among women worldwide, with some 500,000 new cases and 250,000 deaths due to this disease each year. In Europe, there are approximately 50,000 new cases and 25,000 cervical cancer deaths reported annually, while in the US more than 11,000 new cases and 3,800 deaths are expected in 2008.
GSK has licensed Innogenetics' SPF10 primer technology in order to continue its current and future clinical and epidemiological studies in the context of further development of some of their prophylactic vaccines directed against HPV.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.